Skip to main content

Table 2 Chemotherapy regimens, number of cycles and patients’ response to first-line chemotherapy

From: Comparison of the clinical courses and chemotherapy outcomes in metastatic colorectal cancer patients with and without active Mycobacterium tuberculosis or Mycobacterium kansasiiinfection: a retrospective study

Regimens of first-line chemotherapy Overall MTB or MK infection
   (+) (–)
  N = 30 N = 7 N = 23
Intensive regimens 26 6 20
 FOLFOX 8 2 6
 FOLFOX + Bmab 6 1 5
 FOLFIRI 6 1 5
 FOLFOX + Pmab/Cmab 2 2 0
 FOLFIRI + Pmab/Cmab 2 0 2
 FOLFIRI + Bmab 1 0 1
 XELOX 1 0 1
Non-intensive regimens 4 1 3
 UFT/LV 1 1 0
 S-1 2 0 2
 Capecitabine 1 0 1
Response rate (%) 40.0 28.6 43.5
 CR 1 1 0
 PR 11 1 10
 SD 10 2 8
 PD 7 3 4
 NE 1 0 1
  1. CR: complete response, PR: partial response, SD: stable disease, PD: progression disease, NE: not evaluable, RR: response rate.
  2. FOLFOX: folinic acid, fluorouracil, oxaliplatin, Bmab: bevacizumab, FOLFIRI: folinic acid, fluorouracil, irinotecan, Pmab: panitumumab, Cmab: cetuximab, XELOX: capecitabine plus oxaliplatin, UFT/LV: uracil/tegafur/leucovorin.